Granules India Limited · NSE:GRANULES
Granules India — Q3 FY22 Earnings Presentation
15 slides from Granules India's earnings presentation, Feb 8, 2022
Slide 1: Covering letter to stock exchanges: Presentation to Analysts/Investors
G GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLCO12471 Dated February 08, 2022 To, National Stock Exchan
Slide 2: Granules India Limited Q3 Earnings Presentation
Granules India Limited Q3 Earnings Presentation Granules India Limited Q3 Earnings Presentation 1
Slide 3: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Q3 FY22 Financial Highlights
Q3 FY22 Financial Highlights (In ₹ Mn) Income from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins (Rs. Mn.) 4,700 4,648 90.0% 88.0% 86.0% 2,500 60.0% 84.0% 82.0% 2,116 18.0% 4,600 80.0% 78.0% 4,535 76.0% 74.0% 72.0% 50.0% 70.0% 1,737 2,000 68.0% 66.0% 9,968 4,500 5
Slide 5: Geographical Mix
Q3FY22 Revenue spilt by Market, Molecules and Segments (In ₹ Mn) Growth in Europe due to higher Paracetamol sales Finished Dosage and PFI segments grew 8% and 32% Q3FY21 Q3FY22 ROW 9,968 ROW 5.3% 8,445 Geographical Mix 4.8% Segment Revenue India India 14.3% 4,577 FD 16.8% 4,221 PFI North North Latin
Slide 6: Q3FY22 Key Financial and Business Highlights
Q3FY22- Key Financial and Business Highlights Revenue for Q3FY22 stood at INR 9,968 Mn, growth of 18% YoY. FD segment grew by 8%, PFI grew by 32% and API 24% when compared to YoY. Increase in Paracetamol across all the segments by INR 1,077 Mn and increase in other molecules by INR 556 mn in vie
Slide 7: Q3 FY22 Financial Ratios
Q3 FY22 Financial Ratios (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Operational Cash Flow* Free Cash Flow 9,000 8,900 8,800 8,700 1.0 1.3 1.3 1.3 1.3 1.3 1.3 1.2 1,453 506 1,328 8,600 1.2 1.2 8,500 1.2 1.2 8,400 1.2 1.2 8,300 1.2 324 1.2 1.2 0.9 8,200 1.1 8,100 1.1 1.1 8,000 1.1 1.1 7,900 1.1 1.1 7
Slide 8: ANDA/Dossier filing status as of Dec'21
ANDA/Dossier filing status as of Dec’21 GPI IP GIL IP Filing Status Total USA USA Europe Canada South Africa UK Approved 22 24 2 2 50 Tentatively Approved 1 1 2 To be approved 6 6 4 3 2 2 23 Total Products 29 31 6 5 2 2 75 Total GPI products include: ANDA/Dossier filed - Therapeutic area wise CII –
Slide 9: Revenue trend – percentage share from Core and Other Molecules
Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 15% 16% 14% 17% 15% 16% 14% 17% 14% 17% 15% 19% 16% 18% 3% 19% 16% 1%34% 26% 3% 3% 5% 5% 3% 6% 3% 3% 2% 4% 17% 18% 13% 19% 25% 6% 19% 29% 26% 17% 33% 26% 86% 21% 21% 86% 83% 86% 85% 83% 84% 85%
Slide 10: 5-year trajectory: Key Ratios and Cash Flow
5-year trajectory: Key Ratios and Cash Flow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 10,000 3.5 160 1.2 4,000 120.0% 9,082 2,919 9,000 8,704 135 136 3,000 140 125 3.0 100.0% 1,615 1 8,000 3.1 7,232 114 117 2,000 2.5 120 109 9M 6,138 7,000 6,058 0.8 1
Slide 11: 5-year trajectory: Revenue and Profitability
5-year trajectory : Revenue and Profitability (In ₹Mn) Revenue Gross Profit & Gross Margin 35,000 32,375 9M 100.0% 20,000 18,463 170.0% FY22 95.0% 9M FY22 90.0% 18,000 150.0% 30,000 27,349 85.0% 25,986 80.0% 16,000 13,774 130.0% 13,177 75.0% 25,000 22,792 70.0% 14,000 110.0% 65.0% 20,000 16,918 60.0
Slide 12: 5-year trajectory: Market and Segment mix
5-year trajectory: Market and Segment mix (In ₹Mn) Higher revenue contribution coming from FD revenue contribution increased to 52% Finished Dosage contribution going up regulated market, 73% of total revenues from 40% in last 5yrs API PFI FD API PFI FD 5% 5% 4% 6% 5% 40,000 105.0% 15% 14% 13% 20% 2
Slide 13: In Summary
In Summary Timely launches of new products, increasing Investing in People, Technologies, and Process the market share of existing products and innovation to differentiate Granules as a unique expansion of existing products in new brand geographies Continue R&D efforts and ensure robust Improve prof
Slide 14: Glossary
Glossary API: Active Pharmaceutical Ingredient PFI: Pharmaceuticals Formulation Intermediates FD: Finished Dosage OTC: Over the counter drugs Rx: Prescription drugs IR: Immediate Release ER: Extended Release CII: Control substances PFOS: Powder for oral suspensions and solutions MUPS: Multi-unit pel
Slide 15: Corporate address
Mr. Krishna Raghunathan VP Finance and Investor Relations Email: krishna.raghunathan@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Ashish Chovatia +91 9930044680 ashish.chovatia@linkintime.co.in www.orientcap.com 532482 GRANULES Corporate address: GRAN:IN Flo